At a glance

What is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic molecule that inhibits an enzyme called nicotinamide N-methyltransferase, or NNMT. It is not a peptide. Peptides are short chains of amino acids, whereas 5-Amino-1MQ is a small-molecule methylquinolinium¹ compound. It is often grouped with research peptides, but it belongs to a different chemical class.

How does 5-Amino-1MQ work?

NNMT is an enzyme that becomes more active in fat tissue in obesity. In cell studies, inhibiting it increases NAD+ and SAM¹ and suppresses fat production in fat cells. In diet-induced obese mice, a potent NNMT inhibitor reduced body weight and fat mass without changing how much the animals ate. These findings come from animal and cell studies, not from humans.

Is it FDA-approved?

No. 5-Amino-1MQ has never been approved by the FDA for any use and, unlike an approved drug, it has not gone through completed human trials.

What does the research show?

The research is almost entirely preclinical. The main evidence comes from animal and cell work, including these two studies:

There are no completed randomized controlled human trials, so its effects and safety in people remain unknown.

Frequently asked questions

Is 5-Amino-1MQ FDA-approved?

No. 5-Amino-1MQ is not FDA-approved for any indication. It is a preclinical research compound. It is not available by prescription.

Has 5-Amino-1MQ been tested in humans?

No published human clinical trials of 5-Amino-1MQ exist as of September 2026. All reported effects , on body composition, glucose tolerance, and adipocyte biology , come from animal and cell studies. Preclinical findings in rodents do not reliably predict human outcomes.

What does 5-Amino-1MQ do in preclinical adipose tissue studies?

In diet-induced obese mice, 5-Amino-1MQ reduced white fat mass and adipocyte size³ without changing food intake, and a later mouse study found it improved oral glucose tolerance⁴. The proposed mechanism is NNMT inhibition: by preserving SAM in fat cells and blocking the methylation drain, the compound shifts adipose tissue toward greater energy expenditure. Whether this effect occurs in humans has not been studied.

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a methylquinolinium salt , a small synthetic organic molecule, not a peptide. It is often found in the same gray-market channels as peptide compounds and is sometimes searched for alongside peptides, but its chemistry is categorically different.

How does 5-Amino-1MQ compare to semaglutide or tirzepatide?

They operate through entirely different mechanisms. Semaglutide and tirzepatide are GLP-1 receptor agonists⁵ (and GIP agonist in tirzepatide's case⁶) with extensive human trial data and FDA approval for specific indications. 5-Amino-1MQ is an NNMT inhibitor with preclinical animal data only. No human comparison exists. Extrapolating from rodent efficacy data to compare these compounds would be methodologically unsound.

What is the difference between 5-Amino-1MQ and NR or NMN?

NR and NMN are NAD+ precursors that increase cellular NAD+ levels by supplying additional substrate for the salvage pathway. 5-Amino-1MQ inhibits NNMT, the enzyme that diverts nicotinamide away from NAD+ synthesis while also depleting SAM. In principle, the compounds work on adjacent but distinct nodes of the same pathway; 5-Amino-1MQ also addresses the methylation axis that NR and NMN do not. In practice, both NR and NMN have reached small human RCTs, with little metabolic benefit so far: eight NMN trials showed no significant benefit⁷ on glucose or lipid markers, and NR did not improve insulin sensitivity⁸ in obese men. 5-Amino-1MQ has no human data at all.

Can I get 5-Amino-1MQ from a compounding pharmacy?

No. 5-Amino-1MQ is not available by prescription and has no established safety or efficacy profile in humans. Gray-market vendors sell it as a research chemical; those products are not manufactured under pharmaceutical GMP standards and are not subject to regulatory oversight.

What are the risks of using 5-Amino-1MQ?

The human risk profile is unknown because no human safety studies have been conducted. Theoretical concerns include off-target effects of sustained SAM elevation on methylation biology and unknown drug interactions. Long-term effects , including any implications for cancer biology, given NNMT's roles in various cancers⁹ , have not been characterized. Gray-market products carry additional risks related to undetermined purity, dose accuracy, and contamination.

More for digestive & weight